ArticleClinical epigenetics2017
The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Article in Clinical epigenetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.BMC cancer · 2019Pooled it
- Biomarker concordance between primary colorectal cancer and its metastases.EBioMedicine · 2019Pooled it
- DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer.Journal of the National Cancer Institute · 2023Article
- DNA methylation and miRNA expression in colon adenomas compared with matched normal colon mucosa and carcinomas.International journal of experimental pathology · 2022Article
- Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.International journal of cancer · 2021Article
- Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met.Journal of Zhejiang University. Science. B · 2020Article
- Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.Oncology letters · 2020Article
- The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.BMC cancer · 2020Article
- Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study.Bioscience reports · 2019Article
- Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.International journal of molecular sciences · 2019Review
- Methylation Dynamics ofCancers · 2019Review
- Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThe CpG island methylator phenotype (CIMP) in stage III colon cancer (CRC) has been associated with improved survival after treatment with adjuvant irinotecan-based chemotherapy. In this analysis, we determine whether CIMP status in the primary CRC is concordant with the CIMP status of matched metastases in order to determine if assessment of CIMP status in the primary tumor can be used to predict CIMP status of metastatic disease, which is relevant for patient management as well as for understanding the biology of CIMP CRCs.
methodsWe assessed the CIMP status of 70 pairs of primary CRC and matched metastases using a CRC-specific panel of five markers (
resultsSixty-nine of the pairs (98.6%) showed concordant CIMP status in the primary tumor and matched metastasis; five (7.0%) of the pairs were concordantly CIMP positive. Only one pair (1.4%) had divergent CIMP status, demonstrating CIMP positivity (4/5 markers positive) in the primary tumor, while the matched metastasis was CIMP negative (0 markers positive).
conclusionsCIMP status is generally concordant between primary CRCs and matched metastases. Thus, CIMP status in the primary tumor is maintained in matched metastases and can be used to inform CIMP-based therapy options for the metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.